Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106564 | 0.88 | F2 (0.34) | KDM4EF2PTGDR2RXRARXRB | |
| SCHEMBL7108627 | 0.74 | F2 (0.39) | F2THRBPTGDR2 | |
| SCHEMBL7106214 | 0.70 | F2 (0.36) | F2THRB | |
| SCHEMBL7110717 | 0.65 | PTGDR2 (0.42) | PTGDR2KMT2A | |
| SCHEMBL6353530 | 0.64 | NCF1 (0.42) | KDM4EKMT2A | |
| SCHEMBL17700419 | 0.63 | POLB (0.48) | THRBKMT2A | |
| SCHEMBL7107013 | 0.63 | GRM4 (0.39) | PTGDR2 | |
| SCHEMBL16811713 | 0.63 | TSHR (0.35) | CYP2C19SLC6A4KMT2A | |
| SCHEMBL3732073 | 0.63 | F2 (0.44) | KDM4EF2CYP2C19THRBKMT2A | |
| SCHEMBL4832843 | 0.63 | BCL2A1 (0.39) | CYP2C19HIF1AKMT2ACXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | KDM4E 4360/4885F2 1/4885CYP2C19 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.